Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infections
	Primary sponsor	Toyama Chemical Co., Ltd.
	Study Type	Non-interventional
	Summary	To investigate the safety and efficacy of administration of favipiravir (Avigan tablets) for 5 days in patients with novel or re-emerging influenza infections in clinical practice
Details of study	Interventional drug name	Favipiravir (Avigan tablets) 200 mg
	Target illness	Novel or re-emerging influenza infections
	Classification name (code) of the investigational drug	625 (anti-virus agents)
	Administration route	Oral administration
	Control drug name (code/td)	-
	Classification name (code) of the control drug	-
	Administration route	-
	Objectives of the study	To evaluate the safety and efficacy
	Study phase	Other
	Study design	Post-marketing surveillance
	Inclusion Criteria	novel or re-emerging influenza infections who take favipiravir (Avigan tablets) and any gender welcome
	Exclusion Criteria	Pregnant women or women suspected of being pregnant Patients with known hypersensitivity to favipiravir or any of its excipients
	Outcome	Efficacy
	Study status	Preinitiation
	Duration of the study	-
	Region	Japan
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Data Science and Administration Department
	Contact	Form for Inquiry https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn